DelveInsight’s, “Non-Alcoholic Fatty Liver Disease Pipeline Insight, 2023” report provides comprehensive insights about 110+ companies and 160+ pipeline drugs in Non-Alcoholic Fatty Liver Disease  pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Non-Alcoholic Fatty Liver Disease Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Non-Alcoholic Fatty Liver Disease NDA approvals (if any), and product development activities comprising the technology, Non-Alcoholic Fatty Liver Disease  collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Non Alcoholic Fatty Liver Pipeline Report

 

• DelveInsight’s Non Alcoholic Fatty Liver Pipeline report depicts a robust space with 110+ active players working to develop 160+ pipeline therapies for Non Alcoholic Fatty Liver treatment.

 

• The leading Non Alcoholic Fatty Liver Companies includes BeiGene, Inventiva Pharma, Cirius Therapeutics, Madrigal Pharma, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Dr. Falk Pharma GmbH, Sagimet Biosciences, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Afimmune, Poxel SA, AngioLab, Pfizer, Oramed Pharmaceuticals, Can Fite Biopharma, MediciNova, Metacrine, Inc., Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma, Chemomab Therapeutics, NuSirt Biopharma, HK inno.N, Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Enanta Pharmaceuticals, Cascade Pharmaceuticals, and others.

 

• Promising Non Alcoholic Fatty Liver Pipeline Therapies includes ZSP1603, SCO-267, PXS-5382, PXS-5338, Tolimidone, TT-01025, CER-209, DUR-928, EC-18, ID11903, XW003, CB4211, BLD 0409, NPM-159, TB-019, ABP-6016, Nitazoxanide, TERN-301, Research Programme: NASH, MGAT2 Inhibitors, HSD17B13 targeted therapy, Research Programme: NASH, Resmetirom, Oltipraz, Obeticholic Acid, MSDC-0602K, Tirzepatide, TERN-501/TERN-101, TERN-101, SNP-610, LJN452 (tropifexor + licogliflozin), Epeleuton, PXL065, ALS-L1023, ORMD-0801, MET642, and others.

 

• The Non Alcoholic Fatty Liver Companies and academics are working to assess challenges and seek opportunities that could influence Non-Alcoholic Fatty Liver Disease R&D. The Non Alcoholic Fatty Liver therapies under development are focused on novel approaches to treat/improve Non-Alcoholic Fatty Liver Disease.

 

To explore more information on the latest breakthroughs in the Non Alcoholic Fatty Liver Pipeline treatment landscape of the report, click here @ Non Alcoholic Fatty Liver Pipeline Outlook

 

Non Alcoholic Fatty Liver Overview

Non-alcoholic fatty liver disease (NAFLD) is a broad term used to cover a spectrum of conditions that are characterized by evidence of hepatic steatosis on imaging or histology (macro-vesicular steatosis), and absence of secondary causes of hepatic steatosis such as significant alcohol consumption, chronic use of medications that can cause hepatic steatosis or hereditary disorders. The prevalence of NAFLD in western countries is around 20 to 30%. NAFLD is considered to be the liver manifestation of metabolic syndrome. 50 to 70% of people with diabetes are found to have NAFLD. NAFLD has several phases of progression, which include simple steatosis, steatohepatitis, fibrosis, cirrhosis, and ultimately could even progress to hepatocellular carcinoma. The disease has a benign course; it is a silent liver disease when the only histological finding is steatosis. The presence of hepatic injury with inflammation with or without fibrosis constitutes non-alcoholic steatohepatitis (NASH)

 

Latest Developmental Activities in the Non Alcoholic Fatty Liver Treatment Landscape

 

• In September 2022, Inventiva and Chia Tai-Tianqing Pharmaceutical Group entered into a licensing and collaboration agreement to develop and commercialize lanifibranor, if approved, for the treatment of nonalcoholic steatohepatitis and potentially other metabolic diseases in mainland China, Hong Kong, Macau, and Taiwan.

 

• In May 2022, Hepion Pharmaceuticals entered into a clinical collaboration with HepQuant, a Denver-based, privately held company with novel, proprietary investigational technology for evaluating liver function and health in patients with chronic liver diseases. Hepion will incorporate the HepQuant ‘’SHUNT’’ test into a dedicated Phase IIb clinical trial in presumed NASH F3 subjects, initiating in Q3 of this year. 

 

• In January 2022, LISCure Biosciences entered into a research collaboration agreement with Mayo Clinic for new drug development for rare liver diseases. 

 

For further information, refer to the detailed Non Alcoholic Fatty Liver Unmet Needs, Non Alcoholic Fatty Liver Market Drivers, and Non Alcoholic Fatty Liver Market Barriers, click here for Non Alcoholic Fatty Liver Ongoing Clinical Trial Analysis

 

Non Alcoholic Fatty Liver Emerging Drugs Profile

 

Lanifibranor: Inventiva Pharma

Lanifibranor is an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory, and beneficial metabolic changes in the body by activating each of the three PPAR isoforms, known as PPARα, PPARδ, and PPARɣ. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARɣ and partial activation of PPARɣ. It is currently in the Phase III stage of development and is being developed by Inventiva Pharma.

 

Belapectin: Galectin Therapeutics

Belapectin (GR-MD-02) is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer comprising galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. Structural studies have shown that belapectin binds to galectin-1 and galectin-3, with greater binding affinity to galectin-3. Belapectin targets extracellular galectins. Preclinical data in animals have shown that belapectin has robust treatment effects in reversing liver fibrosis and cirrhosis. It is currently in the Phase II/III stage of Clinical trial evaluation for Prevention of Esophageal Varices in NASH Cirrhosis.

 

ZED 1227: Dr. Falk Pharma GmbH

ZED 1227, is a synthetic peptidomimetic compound designed by Zedira scientists to specifically inhibit the enzymatic activity of human tissue transglutaminase (TG2). Dr. Falk Pharma has acquired the licensing rights to ZED1227 in Europe and several non-European countries and has assumed responsibility for pharmaceutical, preclinical, and clinical development of the new chemical entity towards a pharmaceutical product. By inhibiting TG2 in liver tissue, ZED1227 is expected to improve liver fibrosis in patients with NAFLD. It is currently in the phase II stage of development and is being developed by Dr. Falk Pharma GmbH.

 

TVB-2640: Sagimet Biosciences

TVB-2640 is an oral, selective, first-in-class fatty acid synthase inhibitor that directly targets the primary drivers of NASH by reducing excess liver fat (steatosis), decreasing inflammation and blunting fibrosis. In addition to the FASCINATE-2 trial, denifanstat is being tested in a Phase III clinical trial for recurrent glioblastoma and a Phase II study for moderate to severe acne. It is currently in the phase II stage of development and is being developed by Sagimet Biosciences.

 

ALS-L1023: AngioLab

ALS L1023 is a dried extract of ethyl acetate, prepared by activity-guided fractionation from Melissa leaf (lemon balm). The Angiogenesis Inhibitor ALS-L1023 from Lemon-Balm Leaves Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Regulating the Visceral Adipose-Tissue Function. The drug is currently being investigated in Phase II clinical trials for the treatment of patients with Nonalcoholic Steatohepatitis.

 

MN-001: MediciNova

MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound which exerts its effects through several mechanisms to produce its anti-fibrotic and anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. MN-001 has also known to reduce fibrosis in multiple animal models. The drug is currently being evaluated in Phase II stage of development for the treatment of patients with Nonalcoholic Steatohepatitis.

 

Non Alcoholic Fatty Liver Pipeline Therapeutics Assessment

There are approx. 120+ key companies which are developing the therapies for Non-Alcoholic Fatty Liver Disease. The companies which have their Non-Alcoholic Fatty Liver Disease drug candidates in the most advanced stage, i.e. phase III include, Inventiva Pharma.

 

Request a sample and discover the recent advances in Non Alcoholic Fatty Liver Ongoing Clinical Trial Analysis and Medications, click here @ Non Alcoholic Fatty Liver Treatment Landscape

 

Scope of the Non Alcoholic Fatty Liver Pipeline Report

 

• Coverage- Global

 

• Non Alcoholic Fatty Liver Companies- BeiGene, Inventiva Pharma, Cirius Therapeutics, Madrigal Pharma, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Dr. Falk Pharma GmbH, Sagimet Biosciences, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Afimmune, Poxel SA, AngioLab, Pfizer, Oramed Pharmaceuticals, Can Fite Biopharma, MediciNova, Metacrine, Inc., Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma, Chemomab Therapeutics, NuSirt Biopharma, HK inno.N, Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Enanta Pharmaceuticals, Cascade Pharmaceuticals, and others.

 

• Non Alcoholic Fatty Liver Pipeline Therapies includes ZSP1603, SCO-267, PXS-5382, PXS-5338, Tolimidone, TT-01025, CER-209, DUR-928, EC-18, ID11903, XW003, CB4211, BLD 0409, NPM-159, TB-019, ABP-6016, Nitazoxanide, TERN-301, Research Programme: NASH, MGAT2 Inhibitors, HSD17B13 targeted therapy, Research Programme: NASH, Resmetirom, Oltipraz, Obeticholic Acid, MSDC-0602K, Tirzepatide, TERN-501/TERN-101, TERN-101, SNP-610, LJN452 (tropifexor + licogliflozin), Epeleuton, PXL065, ALS-L1023, ORMD-0801, MET642, and others.

 

• Non Alcoholic Fatty Liver Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

 

Dive deep into rich insights for drugs for Non Alcoholic Fatty Liver Market Drivers and Non Alcoholic Fatty Liver Market Barriers, click here @ Non Alcoholic Fatty Liver Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Non-Alcoholic Fatty Liver Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Non-Alcoholic Fatty Liver Disease – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Lanifibranor: Inventiva Pharma
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase  II/III)
11. Belapectin: Galectin Therapeutics
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. ZED 1227: Dr. Falk Pharma GmbH
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. LB-P8: LISCure Biosciences
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Drug name : Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Non-Alcoholic Fatty Liver Disease  Key Companies
24. Non-Alcoholic Fatty Liver Disease  Key Products
25. Non-Alcoholic Fatty Liver Disease  – Unmet Needs
26. Non-Alcoholic Fatty Liver Disease  – Market Drivers and Barriers
27. Non-Alcoholic Fatty Liver Disease  – Future Perspectives and Conclusion
28. Non-Alcoholic Fatty Liver Disease  Analyst Views
29. Non-Alcoholic Fatty Liver Disease  Key Companies
30. Appendix

 

Got Queries? Find out the related information on Non Alcoholic Fatty Liver Mergers and acquisitions, Non Alcoholic Fatty Liver Licensing Activities @ Non Alcoholic Fatty Liver Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/